| umls-concept:C0995188 | skos:definition | NCI: A monoclonal antibody used to treat certain types of head and neck cancer, and colorectal cancer that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Erbitux binds to the epidermal growth factor receptor (EGFR), which is found on the surface of some types of cancer cells.,PDQ: A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division. Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors. This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42384&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42384&idtype=1&closed=1" closed clinical trials using this agent. ("htt | lld:umls |
